期刊文献+

非小细胞肺癌中EGFR基因突变及靶向药物治疗研究进展 被引量:5

在线阅读 下载PDF
导出
摘要 肺癌是世界上最为常见的一种恶性肿瘤,是导致患者死亡的主要原因之一,肺癌的高发病率使非小细胞肺癌患者也日益增多,其作为肺癌中最常见的类型,占所有肺癌的80%,其中75%左右的非小细胞肺癌患者在发现时已经处于中晚期,5年生存率非常低。研究发现非小细胞肺癌的发生可与表皮生长因子受体(EGFR)基因突变相关,尤其在非吸烟者、腺癌、女性等患者中有更突出的表现。因此,对于非小细胞肺癌的发生与EGFR基因突变的关系及非小细胞肺癌的靶向药物治疗是目前临床重要研究课题。
出处 《医疗装备》 2018年第11期203-204,共2页 Medical Equipment
  • 相关文献

参考文献9

二级参考文献91

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J]. CA Cancer J Clin, 2011,61 : 69-90.
  • 2Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008 [ J]. Int J Cancer, 2010, 127 : 2893-2917.
  • 3Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a ohase Ⅱ studv[J]. Clin Cancer Res, 2006, 12: 6049-6055.
  • 4Lee JK, Kim TM, Koh Y, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation[ J]. Lung Cancer, 2012, 77 : 460-463.
  • 5Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China [J]. Lung Cancer, 2012, 77: 371-375.
  • 6Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from 1PASS, a phase Ⅲ study of gefitiuib or carboplatin/paclitaxel in non-small cell lung cancer[ J]. J Thorac Oncol, 2012, 7 : 115- 121.
  • 7Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor ( WJTOG3405 ) : an open label, randomised phase 3 trim [ J ]. Lancet Oncol, 2010, 11 : 121-128.
  • 8Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [J]. N Engl J Med, 2010, 362: 2380-2388.
  • 9Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer ( OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study [ J ]. Lancet Oncol, 2011, 12: 735-742.
  • 10Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxcl as second-line treatment of patients with advanced non- small-cell lung cancer and wild-type EGFR tumours (TAILOR) : a randomised controlled trial[ J]. Lancet Oncol, 2013, 14: 981- 988.

共引文献178

同被引文献52

引证文献5

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部